Go Pro

iRadimed (IRMD) 10K Form and Latest SEC Filings 2026

iRadimed logo
$82.22 +0.35 (+0.43%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$82.12 -0.11 (-0.13%)
As of 09/11/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest iRadimed SEC Filings & Recent Activity

iRadimed (NASDAQ:IRMD) has submitted 461+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in iRadimed's financial statements. The most recent filing was a Form 4 submitted on September 8, 2026.

Form 4
IRADIMED CORP Reports Ownership Change on Sep. 8, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
iRadimed Files Current Report on Aug. 18, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
iRadimed Files Quarterly Report on Jul. 31, 2026

The 10-Q contains iRadimed's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

iRadimed SEC Filing History

Browse iRadimed's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
09/08/2026 3:35 PM
ALLEN MONTY K (1253352) Reporting
iRadimed (1325618) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/03/2026 4:13 PM
ALLEN MONTY K (1253352) Reporting
iRadimed (1325618) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/18/2026 1:03 PM
iRadimed (1325618) Filer
Form 8-K/A
07/31/2026 3:09 PM
iRadimed (1325618) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
07/31/2026 7:15 AM
iRadimed (1325618) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/24/2026 9:22 AM
iRadimed (1325618) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/23/2026 8:29 AM
GLENN JOHN (1253497) Reporting
iRadimed (1325618) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2026 3:21 PM
iRadimed (1325618) Issuer
Scharen-Guivel Hilda Frederique (1950129) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2026 12:00 PM
iRadimed (1325618) Subject
Scharen-Guivel Hilda Frederique (1950129) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/02/2026 1:26 PM
iRadimed (1325618) Issuer
Susi Roger E. (1613801) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/28/2026 2:08 PM
iRadimed (1325618) Issuer
Susi Roger E. (1613801) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/20/2026 3:38 PM
iRadimed (1325618) Issuer
Susi Roger E. (1613801) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/14/2026 4:16 PM
iRadimed (1325618) Subject
Susi Roger E. (1613801) Filed by
Form SCHEDULE 13G/A
05/13/2026 3:30 PM
iRadimed (1325618) Issuer
Susi Roger E. (1613801) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/06/2026 12:51 PM
iRadimed (1325618) Issuer
Susi Roger E. (1613801) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/01/2026 7:45 AM
iRadimed (1325618) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/30/2026 3:19 PM
iRadimed (1325618) Filer
Form ARS
04/30/2026 1:30 PM
iRadimed (1325618) Issuer
Susi Roger E. (1613801) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/22/2026 2:03 PM
iRadimed (1325618) Issuer
Susi Roger E. (1613801) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/15/2026 1:37 PM
iRadimed (1325618) Issuer
Susi Roger E. (1613801) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/07/2026 2:26 PM
iRadimed (1325618) Issuer
Susi Roger E. (1613801) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/01/2026 2:35 PM
iRadimed (1325618) Issuer
Susi Roger E. (1613801) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/25/2026 3:05 PM
iRadimed (1325618) Issuer
Susi Roger E. (1613801) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/18/2026 1:10 PM
iRadimed (1325618) Issuer
Susi Roger E. (1613801) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2026 3:24 PM
iRadimed (1325618) Subject
Susi Roger E. (1613801) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/06/2026 3:05 PM
iRadimed (1325618) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/05/2026 1:42 PM
GLENN JOHN (1253497) Reporting
iRadimed (1325618) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 1:44 PM
Chiprin Jeff (2047489) Reporting
iRadimed (1325618) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/13/2026 2:20 PM
ALLEN MONTY K (1253352) Reporting
iRadimed (1325618) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/13/2026 2:21 PM
ALLEN MONTY K (1253352) Reporting
iRadimed (1325618) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/10/2026 12:20 PM
iRadimed (1325618) Subject
Nine Ten Capital Management LLC (1635236) Filed by
Form SCHEDULE 13G/A
02/10/2026 7:00 AM
iRadimed (1325618) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/13/2026 3:20 PM
iRadimed (1325618) Issuer
Susi Roger E. (1613801) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/06/2026 3:05 PM
iRadimed (1325618) Issuer
Susi Roger E. (1613801) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/30/2025 3:05 PM
iRadimed (1325618) Issuer
Susi Roger E. (1613801) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/22/2025 3:10 PM
iRadimed (1325618) Issuer
Susi Roger E. (1613801) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/17/2025 3:05 PM
iRadimed (1325618) Issuer
Susi Roger E. (1613801) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/15/2025 4:30 PM
ALLEN MONTY K (1253352) Reporting
iRadimed (1325618) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/15/2025 4:30 PM
HAWKINS JAMES B (898243) Reporting
iRadimed (1325618) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/15/2025 4:30 PM
iRadimed (1325618) Issuer
Scharen-Guivel Hilda Frederique (1950129) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/12/2025 4:00 PM
ALLEN MONTY K (1253352) Reporting
iRadimed (1325618) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
“Elon’s nightmare” could fund your retirement (Ad)

Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg terminal, says a new micro cluster AI technology could render today's data centers, including Elon Musk's Colossus in Tennessee, obsolete for major breakthroughs. These next generation centers use 99 percent less space, electricity and water, yet Chaikin's research shows they could be more than a trillion times more powerful than the top data center on earth today, potentially cutting AI breakthrough timelines from five years to five days.tc pixel

See Chaikin's full research and the company name here
12/12/2025 4:00 PM
GLENN JOHN (1253497) Reporting
iRadimed (1325618) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/12/2025 4:00 PM
HAWKINS JAMES B (898243) Reporting
iRadimed (1325618) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/12/2025 4:00 PM
iRadimed (1325618) Issuer
Scharen-Guivel Hilda Frederique (1950129) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/12/2025 4:00 PM
Chiprin Jeff (2047489) Reporting
iRadimed (1325618) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2025 4:10 PM
GLENN JOHN (1253497) Reporting
iRadimed (1325618) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/10/2025 4:00 PM
HAWKINS JAMES B (898243) Reporting
iRadimed (1325618) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/10/2025 4:00 PM
GLENN JOHN (1253497) Reporting
iRadimed (1325618) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/09/2025 4:00 PM
ALLEN MONTY K (1253352) Reporting
iRadimed (1325618) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/09/2025 4:00 PM
iRadimed (1325618) Issuer
Scharen-Guivel Hilda Frederique (1950129) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/09/2025 4:00 PM
HAWKINS JAMES B (898243) Reporting
iRadimed (1325618) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/09/2025 4:00 PM
iRadimed (1325618) Issuer
Susi Roger E. (1613801) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/09/2025 2:22 PM
HAWKINS JAMES B (898243) Reporting
iRadimed (1325618) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/08/2025 7:30 AM
iRadimed (1325618) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/24/2025 4:00 PM
iRadimed (1325618) Issuer
Susi Roger E. (1613801) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/21/2025 3:05 PM
HAWKINS JAMES B (898243) Reporting
iRadimed (1325618) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/20/2025 5:41 PM
HAWKINS JAMES B (898243) Reporting
iRadimed (1325618) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/19/2025 11:05 AM
iRadimed (1325618) Issuer
Susi Roger E. (1613801) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/10/2025 5:54 PM
GLENN JOHN (1253497) Reporting
iRadimed (1325618) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/04/2025 3:05 PM
iRadimed (1325618) Issuer
Susi Roger E. (1613801) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/03/2025 7:30 AM
iRadimed (1325618) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/29/2025 8:20 AM
iRadimed (1325618) Issuer
Susi Roger E. (1613801) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/22/2025 3:05 PM
iRadimed (1325618) Issuer
Susi Roger E. (1613801) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/15/2025 3:05 PM
iRadimed (1325618) Issuer
Scharen-Guivel Hilda Frederique (1950129) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/14/2025 3:05 PM
iRadimed (1325618) Issuer
Susi Roger E. (1613801) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/07/2025 4:00 PM
iRadimed (1325618) Issuer
Susi Roger E. (1613801) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/25/2025 10:30 AM
iRadimed (1325618) Issuer
KIANI JOE E (1228621) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/24/2025 3:05 PM
iRadimed (1325618) Issuer
Susi Roger E. (1613801) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/18/2025 3:15 PM
iRadimed (1325618) Issuer
Susi Roger E. (1613801) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/17/2025 4:33 PM
iRadimed (1325618) Subject
Susi Roger E. (1613801) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
(Data available from 1/1/2016 forward)

iRadimed SEC Filings - Frequently Asked Questions

iRadimed (IRMD) has submitted 461+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

iRadimed's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on iRadimed's financial statements page.

The most recent filing was a Form 4 submitted on September 8, 2026. This was an insider ownership change filed by 4 - IRADIMED CORP (0001325618) (Issuer).

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


SEC filings for NASDAQ:IRMD are sourced directly from the U.S. Securities and Exchange Commission (SEC), with the most recent filing dated 9/8/2026. New filings are added as they're published.
From Our Partners